| Expression System | CHO |
| Aggregation | < 5% as determined by SEC-HPLC |
| Purity | > 95% as determined by SDS-PAGE |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
| Sterility | 0.2 μm Filtered |
| Target | FGFR3 |
| Alternative Names | ACH, CD333, CEK2, HSFGFR3EX, JTK4 |
| Clone | Vofatamab |
| Source/Isotype | Human IgG1, Kappa |
| Application | Flow Cytometry |
| Description | Vofatamab is an anti-FGFR3 monoclonal antibody that acts as an FGFR3 antagonist to block activation of wild-type and gene-activated receptors, it is used to treat metastatic urothelial cancer (MUC, a type of bladder cancer) that carries FGFR3 mutations or fusion genes, which are present in 15% to 20% of patients with advanced disease. The drug inhibits tumor growth by specifically targeting the FGFR3 signaling pathway and has shown significant efficacy in clinical trials in combination with docetaxel or PD-1 inhibitors. |
| Formulation | phosphate-buffered solution, pH 7.2-7.4. |
| Expression System | CHO |
| Aggregation | < 5% as determined by SEC-HPLC |
| Purity | > 95% as determined by SDS-PAGE |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
| Sterility | 0.2 μm Filtered |
| Target | FGFR3 |
| Alternative Names | ACH, CD333, CEK2, HSFGFR3EX, JTK4 |
| Clone | Vofatamab |
| Source/Isotype | Human IgG1, Kappa |
| Application | Flow Cytometry |
| Description | Vofatamab is an anti-FGFR3 monoclonal antibody that acts as an FGFR3 antagonist to block activation of wild-type and gene-activated receptors, it is used to treat metastatic urothelial cancer (MUC, a type of bladder cancer) that carries FGFR3 mutations or fusion genes, which are present in 15% to 20% of patients with advanced disease. The drug inhibits tumor growth by specifically targeting the FGFR3 signaling pathway and has shown significant efficacy in clinical trials in combination with docetaxel or PD-1 inhibitors. |
| Formulation | phosphate-buffered solution, pH 7.2-7.4. |
